In cancer, the pro-angiogenic role of ADAM17 is related to the shedding and activation of different pro-angiogenic factors such as HB-EGF [27], neuregulin-1 [28] or TGF-alpha [29] or, conversely, to the downregulation of the natural inhibitor of angiogenesis thrombospondin-1 (TSP1) [30]. This evidence concerns the gene ADAM17 and cancer.